Cardinal Health, Inc. filings document material events for a healthcare distribution and medical products company, including quarterly results, Regulation FD outlook updates and earnings presentation exhibits. The records tie financial reporting to segment performance, capital returns, debt reduction and corporate finance matters such as revolving credit agreements that support the commercial paper program.
Governance filings cover board composition, annual meeting voting results, director and officer transitions, and related compensation or succession disclosures. The company’s 8-K record also includes material definitive agreements, shareholder voting matters, financial covenants, exhibits and other capital-structure disclosures for Cardinal Health’s public-company profile.
CARDINAL HEALTH INC (CAH) reported that Chief Accounting Officer Mary C. Scherer received a grant of 765 Common Shares on August 15, 2026, representing restricted share units that vest in three equal annual installments beginning August 15, 2027. On the same date, 1,757 Common Shares were withheld and disposed of to satisfy her tax withholding obligations upon the vesting of previously granted RSUs and performance share units, using a reference price of $235.17 per share, which reflects the prior business day’s closing price.
CARDINAL HEALTH INC (CAH) reported equity compensation activity for Chief Human Resources Officer Valerie Christine Pitteroff. On August 15, 2026, she received a grant of 2,977 Common Shares in the form of restricted share units that vest in three equal annual installments beginning on August 15, 2027. On the same date, 1,852 Common Shares were withheld and disposed of at $235.17 per share to satisfy tax withholding obligations arising from the vesting of 1,621 RSUs and 2,610 performance share units; the price reflects the prior business day’s closing price. These transactions were not made pursuant to a Rule 10b5-1 trading plan.
Cardinal Health Inc (CAH) reported that Chief Legal/Compliance Officer Jessica L. Mayer received a grant of 6,378 restricted share units (RSUs), which vest in three equal annual installments beginning on August 15, 2027. On the same date, 25,285 common shares were disposed of through withholding to satisfy her tax withholding obligations related to the vesting of 10,932 RSUs and 46,992 performance share units, valued at a reference price of $235.17 per share. These transactions reflect equity compensation and related tax withholding, not open-market purchases or sales.
For CARDINAL HEALTH INC (CAH), executive Stephen M. Mason, CEO of the GMPD Segment, reported equity compensation activity. On August 15, 2026, he received a grant of 5,868 restricted share units (RSUs) that vest in three equal annual installments beginning August 15, 2027. On the same date, 25,289 common shares were withheld at $235.17 per share to satisfy tax withholding obligations arising from the vesting of 10,966 RSUs and 46,992 performance share units.
CARDINAL HEALTH INC (CAH) reported that Chief Executive Officer Jason M. Hollar received an award of 30,616 Common Shares in the form of restricted share units that vest in three equal annual installments beginning on August 15, 2027. On the same date, 103,449 Common Shares were disposed of to satisfy his tax withholding obligations upon the vesting of 48,021 RSUs and 187,965 performance share units, using a reference price of $235.17 per share, which reflects the prior business day’s closing price.
CARDINAL HEALTH INC (CAH) reported that Chief Information Officer Michelle D. Greene received an equity award and had shares withheld for taxes. She was granted 2,551 restricted share units (RSUs) that vest in three equal annual installments beginning on August 15, 2027. On the same date, 10,031 common shares were withheld at $235.17 per share to satisfy tax withholding obligations arising from the vesting of 6,230 RSUs and 17,230 performance share units.
CARDINAL HEALTH INC (CAH) reported insider equity activity by its Chief Financial Officer, Aaron E. Alt. On August 15, 2026, he received a grant of 8,079 restricted share units (RSUs), which vest in three equal annual installments beginning August 15, 2027. On the same date, 30,730 common shares were withheld at $235.17 per share to satisfy his tax withholding obligations arising from the vesting of 14,075 RSUs and 58,738 performance share units.
Wellington Management Group LLP and affiliated entities report beneficial ownership of Cardinal Health, Inc. common stock on a Schedule 13G. As of June 30, 2026, they collectively report 14,860,271 shares beneficially owned, representing 6.34% of the common stock class.
The filing shows 0 shares with sole voting or dispositive power and shared voting power over 14,221,140 shares, with shared dispositive power over 14,860,271 shares. The securities are held of record by clients of various Wellington investment advisers, which are controlled through a chain of holding companies up to Wellington Management Group LLP, rather than being owned directly by Wellington itself.
Cardinal Health reported solid growth for the fiscal year ended June 30, 2026. Revenue rose 14% to $254.2 billion, driven mainly by branded and specialty pharmaceutical demand, MSO platform acquisitions, and growth in at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight® Logistics. GAAP operating earnings increased 15% to $2.6 billion, while non-GAAP operating earnings rose 30% to $3.6 billion. GAAP diluted EPS grew 12% to $7.23 and non-GAAP diluted EPS rose 37% to $11.26.
Pharma segment profit increased 23% to $2.8 billion, GMPD segment profit rose 91% to $258 million, and Other segment profit grew 37% to $707 million. Cash from operations was $5.2 billion, supporting the $1.9 billion Solaris Health acquisition, $1.4 billion of share repurchases, dividends, and debt repayment; year-end cash was $4.9 billion and debt obligations totaled $8.9 billion. Results were tempered by a $184 million goodwill impairment for Navista & ION, a $122 million impairment on the Outcomes equity interest, higher interest expense, ongoing opioid settlement obligations with $4.3 billion accrued, and tariff-related cost pressures with potential future increases on pharmaceuticals.
Cardinal Health reported strong results for the fourth quarter and fiscal year ended June 30, 2026. Q4 revenue was $63.7 billion, up 6%. GAAP operating earnings rose 70% to $729 million, and GAAP diluted EPS increased 70% to $1.70. Non-GAAP operating earnings grew 30% to $935 million, and non-GAAP diluted EPS rose 40% to $2.91, including a one-time net benefit of $0.31 per share from IEEPA tariff refunds.
For fiscal 2026, revenue grew 14% to $254.2 billion. GAAP operating earnings were $2.6 billion and GAAP diluted EPS was $7.23. Non-GAAP operating earnings increased 30% to $3.6 billion, while non-GAAP diluted EPS rose 37% to $11.26, or $10.95 excluding the IEEPA tariff refund impact. Operating cash flow reached $5.2 billion and non-GAAP adjusted free cash flow was $5.0 billion. All five operating segments delivered double-digit profit growth on a non-GAAP basis.
Management issued fiscal 2027 non-GAAP EPS guidance of $12.40–$12.60, implying 13%–15% growth from adjusted 2026 results, and guided to $3.5–$4.0 billion in non-GAAP adjusted free cash flow. The company repurchased $1.4 billion of shares in fiscal 2026 and the board expanded share repurchase authorization by $5.0 billion to $6.4 billion. A quarterly dividend of $0.5158 per share was declared.